ストックスクリーナーアプリを入手
13.44
3.54%
0.46
プレマーケット:
13.43
-0.010
-0.07%
Greenwich Lifesciences Inc (GLSI) 最新ニュース
Greenwich Lifesciences Inc (GLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GLSI|Greenwich Lifesciences Inc|Price:13.470|Chg%:+0.490 - TradingKey
Form 4 Greenwich Lifesciences Inc For: 27 July By Investing.com - Investing.com Nigeria
Greenwich LifeSciences CEO buys $47,018 in company stock By Investing.com - Investing.com Canada
Greenwich LifeSciences CEO buys $47,018 in company stock - Investing.com
Greenwich LifeSciences (NASDAQ: GLSI) CEO adds 3,600 shares in open-market buys - Stock Titan
Greenwich LifeSciences, Inc. Revenue Breakdown – NASDAQ:GLSI - TradingView
TradingKey - TradingKey
Greenwich Lifesciences Inc (GLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Greenwich Lifesciences Inc (GLSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Greenwich Lifesciences Inc (GLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Greenwich Lifesciences Inc (GLSI) Institutional Confidence - TradingKey
Greenwich Lifesciences Inc (GLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Greenwich LifeSciences, Inc. (GLSI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Greenwich LifeSciences, Inc. (GLSI) stock price, news, quote and history - Yahoo Finance UK
Why Did GLSI Stock Rise Pre-Market Today? - Stocktwits
Greenwich LifeSciences adds up to 10 UK trial sites - grafa.com
Greenwich LifeSciences gains UK approval for breast cancer trial By Investing.com - Investing.com South Africa
Greenwich LifeSciences Gets UK Clearance to Expand Breast Cancer Trial - Moomoo
Greenwich LifeSciences gains UK approval for breast cancer trial - Investing.com
Greenwich LifeSciences secures regulatory approval to expand FLAMINGO-01 trial into United Kingdom - Traders Union
Greenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer Trial - Quiver Quantitative
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom - The Manila Times
UK approval could add 5-10 sites to Greenwich LifeSciences trial - Stock Titan
Greenwich LifeSciences: Building Pivotal Trial Momentum, But Still Not Moving The Needle For Me - Seeking Alpha
Greenwich LifeSciences expands Phase III breast cancer trial - grafa.com
Why is Greenwich LifeSciences stock rallying today? By Investing.com - Investing.com Canada
Greenwich LifeSciences updates phase III breast cancer trial design By Investing.com - Investing.com South Africa
Greenwich LifeSciences updates phase III breast cancer trial design - Investing.com
Greenwich LifeSciences Updates FLAMINGO-01 Phase III Trial Design, Enrollment and Financial Outlook - Quiver Quantitative
Greenwich trial opens enrollment to patients representing about 55% of population - Stock Titan
The Technical Signals Behind (GLSI) That Institutions Follow - Stock Traders Daily
Greenwich LifeSciences wins EMA clearance to combine HLA patient groups in FLAMINGO-01 trial - Bitget
Greenwich LifeSciences expands trial enrollment in Europe By Investing.com - Investing.com South Africa
Greenwich unifies 180-site FLAMINGO-01 trial protocol - grafa.com
Greenwich LifeSciences Announces European Approval For Combining Both HLA Populations In FLAMINGO-01 - marketscreener.com
Greenwich LifeSciences expands trial enrollment in Europe - Investing.com
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01 - GlobeNewswire
Greenwich LifeSciences' breast cancer drug shows strong Phase 2 results but faces funding risks ahead of Phase 3. - Pluang
Greenwich LifeSciences The Overlooked Need (NASDAQ:GLSI) - Seeking Alpha
Greenwich Lifesciences Receives European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 - marketscreener.com
Greenwich LifeSciences (GLSI) Rallies 3.6% as Biotech Stock Approaches Key ResistanceFade Trade - DonanımHaber
Greenwich LifeSciences stock jumps as EMA approves commercial GP2 By Investing.com - Investing.com Canada
Greenwich LifeSciences stock jumps as EMA approves commercial GP2 - Investing.com
Greenwich LifeSciences Secures EMA Approval for Phase 3 GP2 Lot - grafa.com
Sector Update: Healthcare - Moomoo
Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday - Moomoo
Greenwich LifeSciences Says Commercially Manufactured GP2 Cleared for Trial in Europe - Moomoo
European regulators authorize Greenwich LifeSciences to deploy commercial GP2 in FLAMINGO-01 study - Traders Union
Greenwich LifeSciences Announces EMA Approval for Commercially Manufactured GP2 in FLAMINGO-01 Across Europe - Quiver Quantitative
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 - GlobeNewswire
Europe joins U.S. in using commercial GP2 for Greenwich’s breast cancer trial - Stock Titan
Greenwich Lifesciences Inc announced that its commercial production of Gp2 has been approved for use in the Flamingo-01 study in Europe. - Bitget
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):